Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest ROE

Below are the top drugs-generic stocks on the NASDAQ in terms of return on equity. The trailing-twelve-month return on equity at Adamas Pharmaceuticals

is 333.80%. Adamas Pharma's revenue for the same period is $71.10 million. The trailing-twelve-month return on equity at Versartis

is 142.80%. Versartis' current ratio is 3.60. The trailing-twelve-month return on equity at NephroGenex

is 113.30%. NephroGenex's market capitalization is $50.18 million. The trailing-twelve-month return on equity at Aquinox Pharmaceuticals

is 60.90%. Aquinox Pharma's EPS for the same period is -$1.57.